Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Computerized Moderation: Tracking down Equilibrium in the Advanced Age - 2Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- 3Flu cases skyrocket in US. See cases, where people got sick.
- 4British Columbia's Secret Lakeside Town With Hot Springs Is 'An Oasis Of Arts, Culture And Relaxation'
- 5US FDA investigates Takeda's blood disorder drug after pediatric death
- Instructions to Investigate Different Open Record Extra Offers Actually
- Discovery of ancient pleasure boat reveals Egypt's maritime history
- How to watch the 2025 Macy's Thanksgiving Day Parade for free
- Smuggler who called migrants 'chickens' jailed
- What do scientists hope to learn from NASA's historic Artemis 2 moon flyby?
- Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- Flu is rising rapidly, driven by a new variant. Here's what to know
- UN estimates over 2,000 Sudanese pregnant women have fled el-Fasher to escape conflict
- Scientists document a death from a meat allergy tied to certain ticks
